52 reports of this reaction
3.4% of all PROPARACAINE HYDROCHLORIDE reports
#6 most reported adverse reaction
HYPOPYON is the #6 most commonly reported adverse reaction for PROPARACAINE HYDROCHLORIDE, manufactured by Alcon Laboratories, Inc.. There are 52 FDA adverse event reports linking PROPARACAINE HYDROCHLORIDE to HYPOPYON. This represents approximately 3.4% of all 1,545 adverse event reports for this drug.
Patients taking PROPARACAINE HYDROCHLORIDE who experience hypopyon should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOPYON is moderately reported among PROPARACAINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to hypopyon, the following adverse reactions have been reported for PROPARACAINE HYDROCHLORIDE:
The following drugs have also been linked to hypopyon in FDA adverse event reports:
HYPOPYON has been reported as an adverse event in 52 FDA reports for PROPARACAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOPYON accounts for approximately 3.4% of all adverse event reports for PROPARACAINE HYDROCHLORIDE, making it a notable side effect.
If you experience hypopyon while taking PROPARACAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.